Australian Clinical Labs Ltd · ASX:ACL
Australian Clinical Labs — Australian Shareholders' Association Conference 2022
8 slides from Australian Clinical Labs's conference presentation, May 23, 2022
Slide 1: ASX Announcement: Presentation to Australian Shareholders' Association Conference
ASX Announcement Australian Clinical Labs Limited ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia clinicallabs.com.au For personal use only Monday, 23 May 2022 Presentation to Australian Shareholders’ Association Conference Australian Clinical Labs Limited (
Slide 2: Australian Clinical Labs presentation cover
AUSTRALIAN -Clinical>—- CEO ctor 23 May 2022
Slide 3: Agenda
Agenda For personal use only • Introduction • ACL’s journey to global best practice • Video – a sample’s journey • Pathology Innovation • Investment Highlights 1
Slide 4: A leading Australian pathology provider
For personal use only A leading Australian pathology provider targeting global best practice 90+ 1,329 80 31 specialist Hospitals serviced Approved Collection NATA accredited skin cancer clinics, diagnosing ~16% of Leading private Centres laboratories provider in public & reported melanomas in priva
Slide 5: ACL's journey to global best practice
ACL’s journey to global best practice for efficiency, lab technology and IT For personal use only Acquisition / Integration Investment & Innovation Strong Foundations for Growth 2015 2018 2019 2020 2020 Acquisitions • Leaders in service, science, innovation • 2015 Healthscope AU Pathology High
Slide 6: Highly automated laboratory
Highly automated laboratory For personal use only To view video: please click here (https://youtu.be/4K6cgYePV3g) 4
Slide 7: Pathology innovation
Pathology innovation For personal use only Lab Genetics Histopathology & Haematology Advanced new-to-market Digitisation of pathology genetic testing including reporting and use of a non-invasive prenatal algorithmic machine DNA-based blood test learning to provide clinical decision support AI devel
Slide 8: Investment highlights
Investment highlights For personal use only Excluding COVID, Australian pathology is estimated to be a A$5.8 billion market(1), anticipated to grow between 1 ~4% and ~6% p.a. over the five years to FY2025(2) 2 COVID as an endemic virus expected to grow overall pathology market from pre-COVID levels
Australian Clinical Labs — Australian Shareholders' Association Conference 2022 on 6ix